FY2025 Earnings Estimate for NRXP Issued By HC Wainwright

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Equities researchers at HC Wainwright issued their FY2025 earnings per share estimates for shares of NRx Pharmaceuticals in a research note issued to investors on Monday, September 8th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of ($0.57) per share for the year. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ FY2026 earnings at $0.42 EPS.

Several other research analysts also recently weighed in on the stock. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. BTIG Research reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a report on Monday, August 25th. Finally, D. Boral Capital reissued a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research report on Monday. One analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $34.50.

NRx Pharmaceuticals Trading Down 3.0%

Shares of NRXP opened at $2.88 on Thursday. The firm has a market cap of $57.05 million, a PE ratio of -1.29 and a beta of 1.63. NRx Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $6.01. The firm has a fifty day simple moving average of $2.80 and a two-hundred day simple moving average of $2.55.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Monday, August 18th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.67).

Institutional Trading of NRx Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of NRXP. Anson Funds Management LP lifted its position in NRx Pharmaceuticals by 535.1% in the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock valued at $2,417,000 after acquiring an additional 993,401 shares during the last quarter. Geode Capital Management LLC increased its stake in NRx Pharmaceuticals by 27.9% in the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after purchasing an additional 37,598 shares during the period. Millennium Management LLC acquired a new position in shares of NRx Pharmaceuticals during the fourth quarter worth about $61,000. Finally, Squarepoint Ops LLC acquired a new position in shares of NRx Pharmaceuticals during the fourth quarter worth about $56,000. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.